As filed with the Securities and Exchange Commission on February 27, 2025

Registration No. 333-   

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

89bio, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   36-4946844

(State or Other Jurisdiction of

Incorporation or Organization)

 

(I.R.S. Employer

Identification No.)

655 Montgomery Street, Suite 1500

San Francisco, CA 94111

(Address of Principal Executive Offices, Zip Code)

Amended and Restated 89bio, Inc. 2019 Equity Incentive Plan

89bio, Inc. 2019 Employee Stock Purchase Plan

(Full title of the plans)

Rohan Palekar

Chief Executive Officer

89bio, Inc.

655 Montgomery Street, Suite 1500

San Francisco, CA 94111

(Name and address of agent for service)

(415) 432-9270

(Telephone number, including area code, of agent for service)

 

 

Copies to:

Ryan A. Murr

Branden C. Berns

Gibson, Dunn & Crutcher LLP

One Embarcadero Center, Suite 2600

San Francisco, CA 94111

(415) 393-8200

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
Emerging growth company       

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

 

 


EXPLANATORY NOTE

This Registration Statement on Form S-8 is filed by 89bio, Inc. (the “Registrant”), relating to (i) 4,793,977 additional shares of its common stock, par value $0.001 per share (the “Common Stock”), available for issuance pursuant to the Amended and Restated 89bio, Inc. 2019 Equity Incentive Plan and (ii) 1,198,494 additional shares of Common Stock available for issuance pursuant to the 89bio, Inc. 2019 Employee Stock Purchase Plan. The information contained in the Registrant’s registration statements on Form S-8 filed on December 18, 2019 (SEC File No. 333-235577), March 18, 2020 (SEC File No. 333-237263), March 25, 2021 (SEC File No. 333-254683), March 24, 2022 (SEC File No. 333-263838), March 15, 2023 (SEC File No. 333-270544), and March 8, 2024 (SEC File No. 333-277764), together with all exhibits filed therewith or incorporated therein by reference, is hereby incorporated by reference pursuant to General Instruction E to Form S-8.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

 

Item 8.

Exhibits.

 

Exhibit No.

  

Exhibit Description

4.1    Second Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on November 15, 2019).
4.2    Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on June 9, 2023).
4.3    Third Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on November 14, 2023).
5.1*    Opinion of Gibson, Dunn & Crutcher LLP.
23.1*    Consent of Independent Registered Public Accounting Firm.
23.2*    Consent of Gibson, Dunn & Crutcher LLP (included in Exhibit 5.1).
24.1*    Power of Attorney (included on signature page hereto).
99.1    Amended and Restated 89bio, Inc. 2019 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registrant’s Registration Statement on Form S-1/A filed on October 28, 2019).
99.2    89bio, Inc. 2019 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.3 to the Registrant’s Registration Statement on Form S-1/A filed on October 28, 2019).
107.1*    Filing Fee Table.

 

 

*

Filed herewith.


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended (the “Securities Act”), the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Francisco, State of California, on February 27, 2025.

 

89bio, Inc.
By:  

/s/ Rohan Palekar

Name:   Rohan Palekar
Title:   Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Rohan Palekar and Ryan Martins, and each of them, his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this Registration Statement, and any registration statement relating to the offering covered by this Registration Statement and filed pursuant to Rule 462 under the Securities Act, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact and agents or their substitute or substitutes may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, the following persons have signed this Registration Statement in the capacities and on the date(s) indicated.


Signature

  

Title

  

Date

/s/ Rohan Palekar

Rohan Palekar

  

Chief Executive Officer

(Principal Executive Officer)

   February 27, 2025

/s/ Ryan Martins

Ryan Martins

  

Chief Financial Officer

(Principal Financial and Accounting Officer)

   February 27, 2025

/s/ Steven Altschuler, M.D.

Steven Altschuler, M.D.

   Director    February 27, 2025

/s/ Martin Babler

Martin Babler

   Director    February 27, 2025

/s/ Derek DiRocco, Ph.D.

Derek DiRocco, Ph.D.

   Director    February 27, 2025

/s/ Michael Hayden, M.B., Ch.B, Ph.D.

Michael Hayden, M.B., Ch.B, Ph.D.

   Director    February 27, 2025

/s/ Kathleen D. LaPorte

Kathleen D. LaPorte

   Director    February 27, 2025

/s/ Charles A. McWherter, Ph.D.

Charles A. McWherter, Ph.D.

   Director    February 27, 2025


/s/ Edward Morrow Atkinson III

Edward Morrow Atkinson III

   Director    February 27, 2025

/s/ Lota Zoth

Lota Zoth

   Director    February 27, 2025

Exhibit 5.1

 

LOGO

February 27, 2025

89bio, Inc.

655 Montgomery Street, Suite 1500

San Francisco, CA 94111

 

Re:

Registration Statement on Form S-8

Ladies and Gentlemen:

We have examined the Registration Statement on Form S-8 (the “Registration Statement”) of 89bio, Inc., a Delaware corporation (the “Company”), to be filed with the Securities and Exchange Commission (the “Commission”) pursuant to the Securities Act of 1933, as amended (the “Securities Act”), in connection with the offering by the Company of up to 5,992,471 shares of the Company’s Common Stock, par value $0.001 per share (the “Shares”). The Shares are to be issued under the Amended and Restated 89bio, Inc. 2019 Equity Incentive Plan and the 89bio, Inc. 2019 Employee Stock Purchase Plan (collectively, the “Plans”).

In arriving at the opinions expressed below, we have examined originals, or copies certified or otherwise identified to our satisfaction as being true and complete copies, of the originals, of such documents, corporate records, certificates of officers of the Company and of public officials and other instruments as we have deemed necessary or advisable to enable us to render the opinions set forth below. In our examination, we have assumed without independent investigation the genuineness of all signatures, the legal capacity and competency of all natural persons, the authenticity of all documents submitted to us as originals and the conformity to original documents of all documents submitted to us as copies.

We have also assumed that there are no agreements or understandings between or among the Company and any participants in the Plans that would expand, modify or otherwise affect the terms of the Plans or the respective rights or obligations of the participants thereunder. Based upon the foregoing, and subject to the assumptions, exceptions, qualifications and limitations set forth herein, we are of the opinion that the Shares, when issued and sold against payment therefor in accordance with the terms set forth in the applicable Plan as set forth in the Registration Statement, will be validly issued, fully paid and non-assessable.

We render no opinion herein as to matters involving the laws of any jurisdiction other than the Delaware General Corporation Law (the “DGCL”). We are not admitted to practice in the State of Delaware; however, we are generally familiar with the DGCL as currently in effect and have made such inquiries as we consider necessary to render the opinions above. This opinion is limited to the effect of the current state of the DGCL and the facts as they currently exist. We assume no obligation to revise or supplement this opinion in the event of future changes in such law or the interpretations thereof or such facts.

We consent to the filing of this opinion as an exhibit to the Registration Statement, and we further consent to the use of our name under the caption “Legal Matters” in the Registration Statement and the prospectus that forms a part thereof. In giving these consents, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the Rules and Regulations of the Commission.

 

Very truly yours,
/s/ Gibson, Dunn & Crutcher LLP

Gibson, Dunn & Crutcher LLP

One Embarcadero Center Suite 4000 | San Francisco, CA 94111-3715 | T: Tel 415.393.8200 | F: 310.551.8741 | gibsondunn.com

Exhibit 23.1

 

LOGO

KPMG LLP

Suite 1400

55 Second Street

San Francisco, CA 94105

Consent of Independent Registered Public Accounting Firm

We consent to the use of our report dated February 27, 2025, with respect to the consolidated financial statements of 89bio, Inc., and the effectiveness of internal control over financial reporting, incorporated herein by reference.

 

LOGO

San Francisco, California

February 27, 2025

KPMG LLP, a Delaware limited liability partnership and a member firm of

the KPMG global organization of independent member firms affiliated with

KPMG International Limited, a private English company limited by guarantee.

0001785173EX-FILING FEESfalsefalseCommon Stock, par value $0.001 per share (Common Stock) to be issued pursuant to future awards under the Amended and Restated 89bio, Inc. 2019 Equity Incentive Plan (the 2019 Plan)Common Stock to be issued pursuant to future awards under the 89bio, Inc. 2019 Employee Stock Purchase Plan (the ESPP)0.000153100.00015310 0001785173 2025-02-27 2025-02-27 0001785173 1 2025-02-27 2025-02-27 0001785173 2 2025-02-27 2025-02-27 iso4217:USD xbrli:pure xbrli:shares
Exhibit 107.1
CALCULATION OF FILING FEE TABLE
Form
S-8
89bio, Inc.
Table 1 – Newly Registered Securities
 
               
Security Type   
Security
Class
Title
   Fee
Calculation 
Rule
   Amount
Registered
   Proposed
Maximum 
Offering
Price Per
Unit
  
Maximum Aggregate
Offering Price
  
Fee
Rate
   Amount of
Registration
Fee
               
Equity (1)   
Common Stock, par 
value $0.001 per share (“Common Stock”) to be issued pursuant to future awards under the Amended and Restated 89bio, Inc. 2019 Equity Incentive Plan (the “2019 Plan”)
   457(a)    4,793,977    $10.64    $51,007,915.28    $
153.10
 per  $1,000,000
   $7,809.31
               
Equity (2)   
Common Stock to be issued pursuant to future awards under the 89bio, Inc. 2019 Employee Stock Purchase Plan (the “ESPP”)
   457(a)    1,198,494    $9.04    $10,834,385.76    $
153.10
 per $1,000,000
   $1,658.74
           
Total Offering Amounts    5,992,471       $61,842,301.04       $9,468.05
         
Total Fee Offsets             $0
         
Net Fee Due                   $9,468.05
(1)
In addition to the number of shares of the common stock, par value $0.001 per share (the “Common Stock”) of the Registrant stated above, pursuant to Rule 416(c) under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement also covers an indeterminate number of options and other rights to acquire Common Stock that may be granted pursuant to the 2019 Plan. Pursuant to Rule 416(a) under the Securities Act, this registration statement also covers any additional securities that may from time to time be offered or issued in respect of the securities registered by this registration statement to prevent dilution as a result of any stock dividend, stock split, recapitalization or other similar transaction, and any other securities with respect to which the outstanding shares are converted or exchanged. The “Proposed Maximum Offering Price Per Unit” and the “Maximum Aggregate Offering Price” are estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) and Rule 457(h) under the Securities Act, based upon the average of the high and low prices of the Registrant’s Common Stock on The Nasdaq Global Market on February 24, 2025.

(2)
In addition to the number of shares of the Common Stock of the Registrant stated above, pursuant to Rule 416(c) under the Securities Act, this registration statement also covers an indeterminate number of options and other rights to acquire Common Stock that may be granted pursuant to the ESPP. Pursuant to Rule 416(a) under the Securities Act, this registration statement also covers any additional securities that may from time to time be offered or issued in respect of the securities registered by this registration statement to prevent dilution as a result of any stock dividend, stock split, recapitalization or other similar transaction, and any other securities with respect to which the outstanding shares are converted or exchanged. The “Proposed Maximum Offering Price Per Unit” and the “Maximum Aggregate Offering Price” are estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) and (h) under the Securities Act, based upon a 15% discount from the average of the high and low prices of the Registrant’s Common Stock on The Nasdaq Global Market on February 24, 2025, such discount representing the maximum permissible discount offered pursuant to such plan.
v3.25.0.1
Submission
Feb. 27, 2025
Submission [Line Items]  
Central Index Key 0001785173
Registrant Name 89bio, Inc.
Form Type S-8
Submission Type S-8
Fee Exhibit Type EX-FILING FEES
v3.25.0.1
Offerings
Feb. 27, 2025
USD ($)
shares
Offering: 1  
Offering:  
Fee Previously Paid false
Rule 457(a) true
Security Type Equity
Security Class Title Common Stock, par value $0.001 per share (Common Stock) to be issued pursuant to future awards under the Amended and Restated 89bio, Inc. 2019 Equity Incentive Plan (the 2019 Plan)
Amount Registered | shares 4,793,977
Proposed Maximum Offering Price per Unit 10.64
Maximum Aggregate Offering Price $ 51,007,915.28
Fee Rate 0.01531%
Amount of Registration Fee $ 7,809.31
Offering Note
(1)
In addition to the number of shares of the common stock, par value $0.001 per share (the “Common Stock”) of the Registrant stated above, pursuant to Rule 416(c) under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement also covers an indeterminate number of options and other rights to acquire Common Stock that may be granted pursuant to the 2019 Plan. Pursuant to Rule 416(a) under the Securities Act, this registration statement also covers any additional securities that may from time to time be offered or issued in respect of the securities registered by this registration statement to prevent dilution as a result of any stock dividend, stock split, recapitalization or other similar transaction, and any other securities with respect to which the outstanding shares are converted or exchanged. The “Proposed Maximum Offering Price Per Unit” and the “Maximum Aggregate Offering Price” are estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) and Rule 457(h) under the Securities Act, based upon the average of the high and low prices of the Registrant’s Common Stock on The Nasdaq Global Market on February 24, 2025.
Offering: 2  
Offering:  
Fee Previously Paid false
Rule 457(a) true
Security Type Equity
Security Class Title Common Stock to be issued pursuant to future awards under the 89bio, Inc. 2019 Employee Stock Purchase Plan (the ESPP)
Amount Registered | shares 1,198,494
Proposed Maximum Offering Price per Unit 9.04
Maximum Aggregate Offering Price $ 10,834,385.76
Fee Rate 0.01531%
Amount of Registration Fee $ 1,658.74
Offering Note
(2)
In addition to the number of shares of the Common Stock of the Registrant stated above, pursuant to Rule 416(c) under the Securities Act, this registration statement also covers an indeterminate number of options and other rights to acquire Common Stock that may be granted pursuant to the ESPP. Pursuant to Rule 416(a) under the Securities Act, this registration statement also covers any additional securities that may from time to time be offered or issued in respect of the securities registered by this registration statement to prevent dilution as a result of any stock dividend, stock split, recapitalization or other similar transaction, and any other securities with respect to which the outstanding shares are converted or exchanged. The “Proposed Maximum Offering Price Per Unit” and the “Maximum Aggregate Offering Price” are estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) and (h) under the Securities Act, based upon a 15% discount from the average of the high and low prices of the Registrant’s Common Stock on The Nasdaq Global Market on February 24, 2025, such discount representing the maximum permissible discount offered pursuant to such plan.
v3.25.0.1
Fees Summary
Feb. 27, 2025
USD ($)
Fees Summary [Line Items]  
Total Offering $ 61,842,301.04
Total Fee Amount 9,468.05
Total Offset Amount 0
Net Fee $ 9,468.05

89bio (NASDAQ:ETNB)
Historical Stock Chart
From Feb 2025 to Mar 2025 Click Here for more 89bio Charts.
89bio (NASDAQ:ETNB)
Historical Stock Chart
From Mar 2024 to Mar 2025 Click Here for more 89bio Charts.